[Dabigatran versus warfarin in patients with mechanical heart valves].

By D. Fernández de Velasco Pérez. Revista clínica española (Ed. impresa), 2014

606 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/796353df0858d692733e7674f5963e05535900c6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “III: Harm B Anticoagulant therapy with oral direct thrombin inhibitors or anti-Xa agents should not be used in patients with mechanical valve prostheses (200,212,213).”
[2017 ESC/EACTS Guidelines for the management of valvular heart disease]. (2017, methodology): “The use of NOACs is contraindicated.(45) III B”
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, unknown): “VKAs are currently the only treatment with established safety in AF patients with rheumatic mitral valve disease and/or a mechanical heart valve prosthesis.(400)”
Guidelines for the Primary Prevention of Stroke (2011, unknown): “The randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN) trial showed an increase in thromboembolic and bleeding complications with dabigatran compared to warfarin in patients with mechanical heart va”
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “but all occurred in the pericardial space [157].”
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “III: Harm B Anticoagulant therapy with oral direct thrombin inhibitors or anti-Xa agents should not be used in patients with mechanical valve prostheses (200,212,213).”